Who is sponsoring NCT05267977?

NCT05267977 is sponsored by Methodist Health System.

What condition does NCT05267977 study?

NCT05267977 studies Lower Extremity Fracture.

What drugs are being tested in NCT05267977?

Interventions: Cephalosporin 1St Generation, Aminoglycosides.

What is the status of NCT05267977?

NCT05267977 is currently WITHDRAWN.

Last reviewed 2026-03-19 · How we verify

Antibiotic Use & Open Fracture of the Lower Extremity

NCT05267977 Phase 3 WITHDRAWN

It is important to recognize the potential for renal injury and be cognizant of this during the management of complex trauma patients. The primary aim of this study is to investigate the necessity of aminoglycoside usage for patients with open lower extremity fractures. Hypothesis: adding aminoglycoside on top of cephalosporin in treating lower extremity fracture will make no significant difference in term of clinical outcomes when compared to cephalosporin alone.

Details

Lead sponsor	Methodist Health System
Phase	Phase 3
Status	WITHDRAWN
Start date	2016-08
Completion	2022-05-25

Conditions

Lower Extremity Fracture

Interventions

Cephalosporin 1St Generation
Aminoglycosides

Primary outcomes

Aminoglycoside Usage — Within 24 hours of admission
The necessity of aminoglycoside usage for patients with open lower extremity fractures.